The presence of γ′ chain impairs fibrin polymerization by Gersh, Kathryn C. et al.
The presence of γ’ chain impairs fibrin polymerization
Kathryn C. Gersh1, Chandrasekaran Nagaswami3, John W. Weisel, and Susan T. Lord1,2
1Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
2Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599
3Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA
19104
Abstract
Introduction—A fraction of fibrinogen molecules contain an alternatively spliced variant chain
called γ’. Plasma levels of this variant have been associated with both myocardial infarction and
venous thrombosis. Because clot structure has been associated with cardiovascular risk, we examined
the effect of γ’ chain on clot structure.
Materials and Methods—We expressed three fibrinogen variants in Chinese hamster ovary
(CHO) cells: γ/γ homodimer, γ/γ’ heterodimer, and γ’/γ’ homodimer. We observed thrombin-
catalyzed fibrinopeptide release by HPLC, fibrin polymerization by turbidity, and clot structure by
scanning electron microscopy. We characterized post-translational modifications by mass
spectrometry.
Results—Fibrinopeptide A was released at the same rate for all three fibrinogens, while
fibrinopeptide B was released faster from the γ’/γ’ homodimer. The rise in turbidity was slower and
final absorbance was lower during polymerization of γ’-containing fibrinogens than for γ/γ
fibrinogen. Micrographs showed that γ’/γ’ fibrin clots are composed of very thin fibers, while the
diameter of γ/γ’ fibers is similar to γ/γ fibers. Further, the fiber networks formed from γ’-containing
samples were non-uniform. Mass spectrometry showed heterogeneous addition of N-glycans and
tyrosine sulfation in the γ’ chain.
Conclusions—The presence of γ’ chains slows lateral aggregation and alters fibrin structure. We
suggest these changes are likely due to charge-charge repulsion, such that polymerization of the γ’/
γ’ homodimer is more impaired than the heterodimer since these repulsions are partially offset by
incorporation of γ chains in the γ/γ’ heterodimer.
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Fibrinogen is a 340,000 Da dimeric glycoprotein with two copies each of three polypeptide
chains, Aα, Bβ, and γ. A splice variant of the γ chain mRNA that retains the last intron is
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translated into a polypeptide chain called γ’ [1,2]. This alternate chain ends with the 20 residues
VRPEHPAETEYDSLYPEDDL, in place of the last four γ chain amino acids, AGDV [3].
About 10% of fibrinogen molecules incorporate the negatively-charged γ’ chains, forming γ/
γ’ heterodimers [4,5]. Recent epidemiological studies have shown that elevated levels of γ’ are
associated with an increased risk for coronary artery disease, myocardial infarction, and stroke
[6-9], while reduced levels have been correlated with deep vein thrombosis and thrombotic
microangiopathy [10,11]. Biochemical studies have shown the γ’ chain is a high affinity
binding site for thrombin [12,13], accounting for the antithrombin activity of a fibrin clot
[14] as well as the reported role of the γ’ chain in protection from thrombosis [10,11]. The γ’
chain may also serve as a binding site for plasma factor XIII, such that FXIII circulates in a
complex with fibrinogen [15,16].
The conversion of fibrinogen to a fibrin clot is initiated by thrombin-catalyzed cleavage of two
fibrinopeptides, FpA and FpB, to generate fibrin monomers. Fibrin monomers polymerize
spontaneously, forming double-stranded protofibrils that assemble into branched fibrin fibers.
Three groups have examined fibrinopeptide release and fibrin formation in the presence of the
γ’ chain, with little consensus in their findings [17-19]. For example, when fibrin clots were
examined by scanning electron microscopy, Collet et al. showed no difference in morphology
between γ’-containing fibrin clots and those with only γ chains [18]. In contrast, both Cooper
et al. and Siebenlist et al. showed clots of γ’-containing fibrin had thinner fibers and more
branch points than clots with only γ chains [17,19]. While these discrepancies may be due to
differing experimental conditions, it is likely that the source of γ’-containing fibrinogen
contributed to the disparate results. Two groups fractionated plasma fibrinogen into a γ chain
only sample and a sample with both γ and γ’ chains. Because plasma-derived fibrinogen is a
complex mixture of molecules due to post-translational modifications and/or genetic
differences among individuals, it is reasonable to anticipate that the basis for separating these
samples also partitions other fibrinogen characteristics. In addition, plasma proteins,
particularly FXIII, may co-purify selectively with the γ or γ’ fractions [15,16]. The third group,
Collet et al., performed experiments using recombinant human fibrinogens that contained only
γ or only γ’ chains. Thus, studies with the recombinant proteins compared homodimeric
molecules, while those with plasma fibrinogen compared γ chain homodimers to γ/γ’
heterodimers.
To better determine the role of the γ’ chain in polymerization, we synthesized three recombinant
fibrinogens: γ/γ homodimer, γ/γ’ heterodimer, and γ’/γ’ homodimer. Using these proteins, we
were able to compare molecules that differed only by the presence or absence of the γ’ chain
in one or both half-molecules. This is the first study that includes recombinant γ/γ’ heterodimer,




Chemicals were obtained from Fisher (Hampton, NH) or Sigma-Aldrich (St. Louis, MO) unless
otherwise described. Restriction enzymes were purchased from New England Biolabs
(Ipswich, MA), and Taq polymerase, T4 DNA ligase, and penicillin/streptomycin from
Invitrogen (Carlsbad, CA). Expression vectors, DMEM-F12, Nu serum, calf serum, and
aprotinin were previously described [20]. Insulin-transferrin-sodium selenite was from Roche
(Indianapolis, IN) or Sigma-Aldrich. Antibodies were: rabbit anti-human fibrinogen and HRP-
conjugated goat anti-rabbit IgG from DAKO (Carpinteria, CA); goat anti-human fibrinogen
and HRP-conjugated goat anti-human fibrinogen from Cappel (Cochraville, PA); IF-1 calcium-
dependent monoclonal anti-fibrinogen from Kamiya Biomedical (Seattle, WA); 4A5
monoclonal anti-γ chain a kind gift from Dr. Gary Matsueda (Bristol Myers Squibb, Princeton,
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NJ); 2G2H9 monoclonal anti-γ’ chain a kind gift from Dr. David Farrell (Oregon Health and
Sciences University) and purchased from Upstate (Charlottesville, VA). Sepharose Q Fast
Flow Columns and CNBr-activated Sepharose were purchased from Amersham Biosciences
(Piscataway, NJ).
Vector construction
We constructed an expression vector for the γ’ chain by replacing a fragment in the γ cDNA
expression plasmid [20] with the analogous γ’ chain fragment. The plasmid was digested with
BstXI and NotI, the products separated on an agarose gel, and the larger fragment purified
using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA). The γ’ codons were PCR
amplified from human liver cDNA (Stratagene, La Jolla, CA) using the forward primer CAC
GCT GGC CAT CTC AAT GGA GTT TA, including a BstXI site (underlined), and reverse
primer, AGC ATT TGC GGC CGC CTA CAA ATC ATC CTC A, including a NotI site
(underlined). Oligonucleotides were prepared by the UNC-Chapel Hill Pathology Department
Oligonucleotide Synthesis Facility. The PCR product (0.05 μg) was digested using BstXI and
NotI, purified as described above, and ligated to the expression plasmid fragment (0.05 μg)
with T4 DNA ligase. The ligated DNA was transformed into competent DH5α cells. The entire
cDNA in candidate clones was sequenced by Taq Dye Terminator Sequencing at the UNC
Genome Analysis Facility.
Expression of γ’-containing fibrinogens
CHO cell lines expressing γ’-containing fibrinogens were prepared essentially as described
[20]. For the γ’/γ’ clone 18 μg of plasmid pMLP-γ’ was transfected into CHO cells that
expressed the Aα and Bβ chains of fibrinogen; for the γ/γ’ clone transfections contained 18
μg of pMLP-γ’ and 36 μg of pMLP-γ. Clones were screened by ELISA, measuring the
fibrinogen secreted into serum-free medium, and those expressing the highest levels of
fibrinogen were subcloned by infinite dilution. In addition to fibrinogen concentration, clones
expressing γ/γ’ fibrinogen were also screened for the ratio of γ to γ’ chains by Western blot of
media concentrated with 100 kDa MWCO Centricon Eppendorf concentrators to ≤ 0.01 μg/
μL fibrinogen. SDS-PAGE was run under reducing conditions at 60-80V on an 11% gel with
a tall stacking gel. Blots were developed using a polyclonal anti-fibrinogen antibody, and the
ratio of γ: γ’ chains quantified by densitometry using Scion Image (SCIONCorp, Frederick,
MD). Clones expressing the highest levels of fibrinogen with near equal ratios of γ and γ’
chains were subcloned; this subclone had 63% γ’ chains. Thus, the anticipated percentage of
heterodimers (2*[γ chains]*[γ’ chains]) was 47%.
Fibrinogens were synthesized as described [20], with the following modifications. Microcarrier
beads were omitted, cells were grown for six days in serum-free media, and 50 mL of
fibrinogen-containing media were collected and replaced each day until cell death about 3
weeks later. Before freezing at -20°C, 0.01% NaN3 and protease inhibitors (30 μM
benzamidine, 6μM EDTA, 0.15mM PMSF) were added. Regular γ/γ homodimer fibrinogen
was synthesized from the described cell line [20].
Fibrinogen purification
All fibrinogens, γ/γ homodimers, γ/γ’ heterodimers, and γ’/γ’ homodimers, were purified from
media using an IF-1 calcium-dependent monoclonal anti-fibrinogen immunoaffinity column
as described [21]. Eluted fibrinogen was dialyzed into HBS (20 mM HEPES pH 7.4, 150 mM
NaCl).
Fibrinogen from the γ/γ’ heterodimer clone medium was further purified, to separate the desired
heterodimer from the two contaminating homodimers, as all three variants (γ/γ and γ’/γ’
homodimers, as well as γ/γ’ heterodimers) were produced by the γ/γ’ cell line. We prepared
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an immunoaffinity column (4 mL) by coupling γ chain-specific monoclonal antibody 4A5 to
CNBr-activated Sepharose according to the manufacturer’s protocol. The column was
equilibrated in 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1mM CaCl2 (LB), and 2 mg fibrinogen
(a mixture of γ/γ, γ/γ’, and γ’/γ’) diluted to 1 mg/mL in LB was applied to the column at 10
mL/hour. Homodimer γ’/γ’ fibrinogen flowed through during loading. The column was washed
at 50 mL/hour for 10 minutes with LB. Bound fibrinogens (γ/γ and γ/γ’) were eluted with 1M
guanidinium-HCl in 50 mM Tris-HCl pH 7.4, 150 mM NaCl (TBS) at 20 mL/hour, and the
fractions containing fibrinogen were immediately dialyzed against 1L LB and subsequently
3X 1L of TBS. Dialyzed samples were concentrated to 1-4 mg/mL (Amicon Ultra 100,000
MWCO Centrifugal Filter Devices) and further separated by loading 0.2 - 0.5 mgs onto a 1
mL Sepharose Q Fast Flow ion-exchange column equilibrated in buffer A (39 mM Tris pH 8.5
with H3PO4) at 1 mL/minute. Proteins were eluted with a linear gradient of 0 - 100% buffer B
(190 mM Tris pH 2.4 with H3PO4) over 40 minutes, a procedure analogous to that used to
separate γ/γ from γ/γ’ fibrinogen in plasma [15]. The fractions with γ/γ’ heterodimers, which
eluted from our column at 55% buffer B, were collected, extensively dialyzed into HBS, and
concentrated.
Fibrinogen concentration was measured spectrophotometrically (A280 = 1.51 for 1 mg/mL).
The purity and chain composition were analyzed by SDS-PAGE.
Mass spectrometry
Peak 2 fibrinogen from human plasma (Enzyme Research Laboratories, South Bend, IN) was
reduced and the γ and γ’ chains isolated as a single fraction by HPLC (Shimazdu) essentially
as described [13], but using a Supelco Discovery C-18 column and eluting the chains with a
linear gradient from 40-60% buffer B, where buffer A was 0.1% TFA and B was 0.1% TFA
in acetonitrile. Recombinant fibrinogens, 300 μL of 1 mg/ml in 8 M urea, 0.1 M Tris-HCl, pH
8.0, were reduced with 20 mM dithiothreitol for 4 hrs at 37° C. Acetic acid was added to 10%
and 100 μL of sample was fractioned by HPLC as above. In contrast to plasma fibrinogen, only
two peaks were resolved. These were collected, analyzed by SDS-PAGE, and found to contain
α chains and a mixture of β and γ chains or a mixture of β and γ’ chains.
Mass spectrometry was performed by the UNC-Duke Michael Hooker Proteomics Center.
Samples containing the mixed chains were lyophilized and dissolved in 10 μL DI water. A
one-μL aliquot was diluted with 5 μL of methanol:water:acetic acid, 75:23:2, and 5 μL placed
into an ES381 Au/Pd-coated borosilicate nanospray needle (Proxeon Biosystems, Odense,
Denmark). Samples were analyzed by nano-electrospray on an AB Q-Star Pulsar QqTOF
(Applied Biosystems, Foster City, CA) mass spectrometer operating in the positive ion mode.
Spectra were acquired over the mass range 400-2000 Da, scanned every 2 s, with an ionspray
voltage of 1000-1200 V. The resulting ion signals were averaged over a maximum of 5 minutes.
Calibration was done using the renin substrate MS/MS spectrum, acquired over this same mass
range. Data were acquired and processed using AB’s BioAnalyst software and deconvoluted
to singly-charged species using the maximum entropy (MaxEnt) software provided by the
manufacturer.
Fibrinopeptide release
Fibrinopeptide release was performed as described [20] with 0.1 mg/ml fibrinogen in HBS,
pH 7.4 with 1.0 mM CaCl2 catalyzed by 0.10 nM (0.01 U/mL) thrombin. Fibrinopeptides were
analyzed by HPLC with peak areas compared to synthetic FpA and FpB standards. Data were
plotted as % fibrinopeptide released and first order rate constants were determined as described
[20].
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Polymerization was monitored by turbidity at 350 nm as described [22], with the following
modifications. Reactions, 100 μL, were performed in Corning half-area untreated polystyrene
microtiter plates (sample pathlength of 0.56 cm) with 0.15 mg/mL fibrinogen in HBS at three
concentrations of calcium, 10 μM, 2.0 mM, or 5.0 mM. The NaCl concentration was adjusted
to maintain ionic strength of 0.15. Polymerization was initiated by the addition of 1 nM (0.1
U/mL) thrombin.
Scanning electron microscopy
Clots were prepared in HBS + 2.0 mM CaCl2, by incubating 1.0 mg/mL fibrinogen and 0.10
U/mL thrombin at room temperature for 1 hour. Samples were prepared for microscopy as
described, including fixing, dehydration, critical point drying, and sputter coating in gold-
palladium [23]. Images were acquired digitally on a Phillips XL20 scanning electron
microscope (FEI Company, Hillsboro, OR). Fiber diameters were measured in Image J v.1.37
(Wayne Rasaband, NIH) by using a line to bisect foreground fibers in 10,000X magnification
images.
Results
Expression, purification, and characterization of recombinant fibrinogens
To our knowledge, this is the first time in which γ/γ’ fibrinogen heterodimers have been
expressed by CHO cells and isolated from the contaminating homodimers found in the media.
To determine whether fibrinogen function was impaired by 4A5 chromatography, we did
control experiments with recombinant γ/γ fibrinogen. We found that polymerization of γ/γ
fibrinogen was not altered by this step (data not shown). Purified fibrinogens were
characterized by SDS-PAGE under reducing conditions (Figure 1). Comparing the band
patterns for the γ’/γ’ homodimer to the γ/γ homodimer confirmed that migration of the γ’ chain
was intermediate between the Bβ and γ chains, as previously shown in plasma fibrinogen
[24]. Densitometry showed approximately equal amounts of γ and γ’ chains in the purified γ/
γ’ heterodimer. The SDS-PAGE also showed all three fibrinogens were pure. Each fibrinogen
had some Aα chain degradation, with more for the heterodimer relative to either of the
homodimers. This level of Aα degradation is common, especially with plasma fibrinogen
[21].
Because tyrosine sulfation of the γ’ chain is important for thrombin binding [25,26], we
examined modification of the recombinant γ’ chain by mass spectrometry. As a control, we
analyzed plasma fibrinogen peak 2 by electrospray mass spectrometry. We separated chains
by HPLC and analyzed a mixture of γ and γ’ chains. The mass of the mono-sialylated form of
the γ chain was 48,367 Da, which is close to the calculated value of 48,383 Da. The mass of
the monosialylated form of the γ’ chain was 50,562 Da, which is 164 Da greater than the value
calculated for the non-sulfated chain (50,398), indicating both tyrosines are sulfated (80 Da
per sulfate group). This finding is consistent with previous reports [13]. We then analyzed both
γ/γ and γ’/γ’ fibrinogens, separating the reduced chains using the same HPLC procedure as for
plasma fibrinogen. With both proteins, the Bβ and γ chains eluted together, as shown by SDS-
PAGE (data not shown). The mixtures were analyzed by electrospray mass spectrometry as
described in methods. The spectra contained multiple peaks for each chain (Figure 2),
consistent with heterogeneous addition of N-glycans as previously reported for human proteins
synthesized in CHO cells [27]. For γ fibrinogen the two most abundant peaks were 48,079 Da
and 47,916 Da, or 1611 and 1448 Da more than the mass predicted from the amino acid
sequence of the γ chain (46,468 Da). These masses are consistent with the biantennary glycans
Gal1GlaNAc4Man3Fuc1 and GlaNAc4Man3Fuc1, respectively. All the Bβ chain peaks were
less abundant than those for γ; the two most abundant were 53,915 Da and 54,079 Da, 1600
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Da and 1764 Da higher than the mass calculated from the sequence of the encoded Bβ isoform
(52,315 Da). These masses are consistent with the addition of Gal2GlaNAc4Man3Fuc1 and
Gal1GlaNAc4Man3Fuc1. For γ’ fibrinogen the most abundant peak was that from the Bβ chain
with a mass of 54,091 Da, 1776 Da higher than the Bβ chain indicating addition of
Gal2GlaNAc4Man3Fuc1. The next peaks of approximately equal abundance were 50,422 Da
and 50,340 Da, 1939 Da and 1857 Da higher than the calculated mass of the γ’ chain (48,483
Da), indicating addition of Gal2GlaNAc4Man3Fuc1 and 2 or 1 sulfates, respectively. Thus the
γ’ chains are sulfated, with about half having sulfate on both tyrosine residues.
Fibrinopeptide release
We measured the kinetics of fibrinopeptide release using HPLC to quantify changes in peptide
concentration with time. As shown in Figure 3, the rate of thrombin-catalyzed FpA release was
similar for all three variants, while FpB release from γ’/γ’ fibrinogen was faster than from
either γ/γ or γ/γ’ fibrinogen. We fit the data to two sequential first-order rate equations to
determine the rate constants [20]. FpA release constants were the same for all three variants
(γ/γ = 12 +/- 1 × 10-3 s-1; γ/γ’ = 12 +/- 1 × 10-3 s-1; γ’/γ’ = 13 +/- 1 × 10-3 s-1). FpB release
from γ’/γ’ fibrinogen was 1.5-fold faster than FpB released from γ/γ or γ/γ’ fibrinogen (γ/γ =
7.8 +/- 0.6 × 10-3 s-1; γ/γ’ = 8.6 +/- 0.5 × 10-3 s-1; γ’/γ’ = 12 +/- 1 × 10-3 s-1; p < 0.002).
Fibrin polymerization
We monitored thrombin-catalyzed polymerization by turbidity. From the curves shown in the
upper row of Figure 4, we determined the lag time, maximal slope and final absorbance as
described [22]; the data are shown in Table 1. Polymerization of both γ’ variants clearly differed
from γ/γ fibrinogen. The maximal slope and final absorbance were lower for the heterodimer
with one copy of the γ’ chain than for γ/γ fibrinogen, and in turn, these were lower for γ’/γ’
fibrinogen with two copies of the γ’ chain than for the heterodimer. These findings suggest the
γ’ chain slowed lateral aggregation and reduced fiber diameter. In contrast, with one exception,
the γ’ chain did not influence the lag times (lower row of Figure 4). This exception was γ’/γ’
fibrinogen at low calcium concentration, where the lag time was significantly longer. This
finding suggests that at the low Ca2+ concentration without cations to offset their electrostatic
repulsion, the additional negative charges of two γ’ chains hindered monomer assembly into
protofibrils.
Because calcium affects fibrinogen polymerization, we monitored the variants at three Ca2+
concentrations: 10 μM, where calcium is bound only in the high affinity sites, 2.0 mM, which
is near physiological, and 5.0 mM, which is similar to that used in previous γ’ studies [17,
18]. An increase in calcium from 10 μM to 2 mM increased both the rate and the final
absorbance of γ/γ fibrinogen polymerization, but further increasing calcium to 5 mM did not
enhance these values. The same trend was found for both γ/γ’ and γ’/γ’ fibrinogens. With the
exception noted above, the changes in calcium did not impact lag times.
Scanning electron microscopy
We prepared clots for microscopy according to the method of Weisel and Nagaswami [23].
Representative low magnification images from each sample are shown in Figure 5A while high
magnification images are shown in Figure 5B. We measured fiber diameters from ten 10,000X
magnification images. As expected from the turbidity results, γ’/γ’ fibrin clots were composed
of significantly thinner fibers (average fiber diameter = 0.17 +/- 0.04 μm from 500 fibers
measured) than γ/γ fibrin clots (average fiber diameter = 0.25 +/- 0.06 μm from 447 fibers
measured; p < 0.01). The γ’/γ’ clots were also more tightly packed with smaller pores and more
branching. In contrast to the uniform structure of the γ/γ clots, the thin γ’/γ’ fibers appeared to
loosely form into bundles that produced large pores in addition to the smaller pores of the clots
(see arrows in Figure 5A). Contrary to our expectations from the turbidity data, the γ/γ’ fibrin
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clots (average fiber diameter = 0.27 +/- 0.05 μm from 291 fibers measured) did not have thinner
fibers than γ/γ fibrin clots; in fact they were slightly thicker (p < 0.01). However, turbidity is
related to fiber diameter only if the fibers are uniformly distributed in the clot. In this case, the
fiber arrangement was decidedly non-uniform. The γ/γ’ clots had bundles of fibers and pores
like the super-structure of the γ’/γ’ clots. The large open spaces in these clots could account
for the decrease in turbidity for γ/γ’ fibrin compared to γ/γ fibrin. In addition, the γ/γ’ clots
contained a large number of free fiber ends (see arrows in Figure 5B). Fiber ends are normally
found at low levels in scanning electron micrographs of fibrin clots, and have been suggested
to arise from early truncation of protofibril formation or lateral aggregation [28,29].
Discussion
Our investigation is the first to study all three possible combinations of γ and γ’ chains: γ/γ
homodimer, γ/γ’ heterodimer, and γ’/γ’ homodimer. By using these recombinant fibrinogens
rather than the comparable species from plasma, we avoided inter-individual variability, as
well as contamination by co-purifying plasma proteins. Importantly, our common method of
synthesis allowed comparison of fibrinogens that differed only in the region of interest: the
alternative forms of the C-terminus of the γ chain. Although the γ’/γ’ homodimer is only found
in < 1% of plasma fibrinogen molecules [24], studying it here provided us with a way to isolate
the role of the γ’ chain in fibrin clot structure.
We have shown by electrospray mass spectrometry that the γ’ chain is expressed by CHO cells
with the biantennary N-glycan Gal2GlaNAc4Man3Fuc1 and one or two sulfates. Our data show
that the γ’ chains are sulfated, with about half doubly sulfated. Because tyrosine sulfation is
important for thrombin binding and yet binding can still take place even when only one tyrosine
is sulfated [25,26], we conclude that our recombinant γ’ fibrinogen is a good model for plasma
γ’ fibrinogen.
Although binding of thrombin to the γ’ chain has been described as inhibitory to its activity
[14], we found the γ’ chain had no effect on fibrinopeptide A release since all three variants
displayed identical kinetics for release of FpA. Fibrinopeptide B was released more quickly
from γ’/γ’ than from either γ/γ or γ/γ’ fibrinogens. Previous studies suggest FpB is likely
released from E nodule when it is bound to the DD interface in protofibrils [30,31]. As the γ’
chain contains a high-affinity thrombin binding site [12], our data suggest that the juxtaposition
of two γ’ chains at the DD interface in γ’/γ’ protofibrils brings a high concentration of thrombin
to this locale enhancing FpB release. The binding of thrombin to the γ’ chain has previously
been suggested as a way to localize thrombin to the fibrin clot as blood continues to flow
[32].
Measuring polymerization by turbidity, we found the lag time was not influenced by the γ’
chain, except at the lowest concentration of calcium (10 μM). We conclude that the γ’ chain
does not alter the rate of protofibril formation at physiological calcium concentration. In
contrast, we found the maximal slope and final absorbance were reduced in the presence of the
γ’ chain. When compared to the kinetic model of polymerization developed by Weisel and
Nagaswami [23], these differences suggest the γ’ chain leads to an increase in the rate of fiber
initiation and thus a decrease in lateral aggregation and formation of thinner fibers. This
interpretation is consistent with the SEM images of clots prepared from the γ’/γ’ homodimer
that do, indeed, exhibit thinner fibers compared to the γ/γ homodimer. While the γ/γ’
heterodimer turbidity profile suggests a rate of lateral aggregation and final turbidity
intermediate between the two homodimers, the micrographs showed heterodimer fiber
diameters are of similar width as the γ/γ homodimer. Fibers in the γ/γ’ clots were much more
loosely and non-uniformly packed, which would account for the decreased turbidity. We
propose that the γ’ chain impairs lateral aggregation of the γ’/γ’ clot by charge-charge repulsion,
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but in the heterodimer clot, the interspersing of γ and γ’ chains allows fibers of normal width
to form. However, periodically, the alignment gets disturbed when multiple γ’ ends come
together. The proximity of these negatively charged regions caps the fiber and terminates
polymerization. A similar model was proposed by Woodhead and colleagues to explain why
fibrinogen Caracas II (a mutation that affects the αC domain of 50% of fibrinogen molecules
in affected individuals) forms fibrin networks with large and small pores and many free fiber
ends [28].
Although our studies contribute novel data, they do not, unfortunately, resolve the
inconsistencies reported in previous work. Previous studies of γ’-containing fibrinogens were
performed under a variety of conditions and with different sources of fibrinogen (Table 2).
Internal inconsistencies make it impossible to reconcile all of the results, even if we were to
repeat each of the previous experiments with our recombinant fibrinogen. Our fibrinopeptide
release results are not consistent with either of the other two fibrinopeptide release studies,
which were also inconsistent with one another. These previous studies examined fibrinogens
fractionated from plasma so cleavage of γ’/γ’ homodimers was not measured. Thus our finding,
the increased rate of FpB release from the γ’/γ’ homodimer, is novel. In contrast, our finding
of normal rates for both FpA and FpB release from γ/γ’ heterodimer conflicts with the published
data. Comparing the γ/γ’ heterodimer to γ/γ homodimer, Cooper et al. found normal FpA and
delayed FpB release while Siebenlist et al. found FpA and FpB release were both delayed. The
differences among the three reports likely reflect experimental conditions as our experiments
were completed in the absence of FXIII and with 1 mM CaCl2, Siebenlist’s in the presence of
FXIII but without added calcium, and Cooper’s in the absence of added FXIII or calcium. One
can speculate that FXIII, which is also a thrombin substrate, might inhibit release of both
fibrinopeptides as was observed by Siebenlist et al.; and that the lack of calcium might slow
FpB release, as release of this fibrinopeptide depends on the rate of polymerization which is
slower at μM concentrations of calcium.
Our clot morphology data also differ from the published studies. We found the heterodimer
forms clots with the same fiber diameter as the γ/γ homodimer, while Cooper et al. and
Siebenlist et al. both found these fibers were thinner. Heterogeneities unrelated to the γ’ chain
that partitioned during purification of fractions from plasma could explain these differences.
Another possibility is that the γ’ containing fibrinogens prepared from plasma may be
contaminated with bound Factor XIII that affects fibrin polymerization. We also found clots
of the γ’/γ’ homodimer had thinner fibers than those formed from γ/γ homodimer, while Collet
et al. found fibers in these two clots prepared from recombinant fibrinogens were not different.
Although Collet’s experiments included FXIII, used a slightly higher calcium concentration
than we did (5 mM vs. 2 mM), and a substantially higher thrombin concentration (0.9 U/mL
vs 0.1 U/mL), it is unclear how these different conditions account for the discrepancies between
these two studies.
In conclusion, these studies with recombinant fibrinogens allowed direct comparison of all
three γ’ chain variants, the two homodimers and the heterodimer. Our data have shown that
the γ’ chain per se modulates polymerization, in particular it slows lateral aggregation of
protofibrils. Moreover, our microscopy data showed the presence of the γ’ chain altered clot
structure, introducing a non-uniform structure. Because clot structure has been correlated with
thrombotic risk, our findings can be related to the potential role of γ’ in disease. Individuals
with increased γ’ chain levels will have increased proportions of both γ/γ’ heterodimers and
γ’/γ’ homodimers. Our findings predict a clot with more γ’ chains would be more heterogeneous
than one composed of fewer γ’-containing molecules. One could expect not only more areas
with thinner fibers and tighter pores, structures associated with increased thrombotic risk, but
also more areas with bundled fibers and larger pores, structures associated with reduced risk
[33]. Our results are therefore consistent with the apparently conflicting epidemiologic studies
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that suggest elevated γ’/γ ratios may be either a risk factor for or protection from thrombotic
disease. The heterogeneous structures we have observed may lead to a heterogeneous
phenotype. Further in vivo studies are necessary to fully understand the contribution of γ’ chains
to the etiology of thrombotic disease.
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Figure 1. SDS-PAGE of Purified Fibrinogens
Samples (3 μg) of γ/γ’, γ/γ, and γ’/γ’ fibrinogen and an equimolar (1.5 μg of each) mixture of
γ/γ and γ’/γ’ fibrinogen were electrophoresed on an 11% SDS-PAGE gel under reducing
conditions. Bar shows the excision of empty lanes between samples.
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Figure 2. Mass spectra of recombinant fibrinogens
Samples containing a mixture of Bβ and γ chains isolated from γ’/γ’-(panel A) and γ/γ-(panel
B) fibrinogens were analyzed by electrospray mass spectrometry. In panel A, the pair of peaks
marked by the * are consistent with tyrosine sulfation of one (50,340 Da) or both (50,422 Da)
tyrosines in the γ’ chains. The mixture of γ chain peaks in panel B (48,079 Da and 47,916 Da)
arises from heterogeneous addition of N-glycans to the chain.
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Figure 3. Kinetics of Fibrinopeptide Release
FpA (closed symbols) and FpB (open symbols) release from fibrinogen γ/γ (circles), γ/
γ’ (squares), and γ’/γ’ (triangles). Reactions contained 0.1 nM (0.01 U/mL) thrombin and 0.1
mg/ml fibrinogen in HBS with 1 mM CaCl2, as described in Materials and methods.
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Figure 4. Averaged Polymerization Curves
Polymerization was initiated by addition of 1.0 nM (0.10 U/mL) thrombin to 0.15 mg/mL
fibrinogen at three concentrations CaCl2, 10 μM (A), 2.0 mM (B), and 5.0 mM (C). Turbidity
was monitored at 350 nm for 90 minutes (upper panels); the first 13 min are shown in greater
detail in the lower panels. Curves are the mean of 3 experiments. Error bars are ± 1 standard
deviation.
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Figure 5. Scanning Electron Micrographs
Clots were prepared from γ/γ homodimer, γ/γ’ heterodimer, and γ’/γ’ homodimer by addition
of 0.10 U/mL thrombin to 1.0 mg/mL fibrinogen in HBS + 2.0 mM CaCl2 (final concentration).
Samples were prepared for microscopy as described in Materials and methods. Images were
acquired digitally on a Phillips XL20 scanning electron microscope (FEI Company, Hillsboro,
OR). In low magnification images (A) the scale bar indicates 10 μm and arrows point to fiber
bundles. In high magnification images (B) the scale bar indicates 2 μm and arrows point to
free fiber ends.
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Table 1
Polymerization of γ/γ, γ/γ ’, and γ’/γ’ Fibrin
Polymerization was monitored by turbidity at 350 nm for each variant as described in Materials and methods.
γ/γ γ/γ’ γ’/γ’
Lag Time, sec
10 μM CaCl2 117 +/- 12 120 +/- 30 175 +/- 7*†
2.0 mM CaCl2 100 +/- 20 83 +/- 25 97 +/- 12
5.0 mM CaCl2 103 +/- 25 75 +/- 7 90 +/- 17
Maximal Rate, milliunits/min
10 μM CaCl2 83 +/- 8† 26 +/- 6*† 11 +/- 0.2*†
2.0 mM CaCl2 108 +/- 7 40 +/- 8* 19 +/- 4*
5.0 mM CaCl2 108 +/- 17 50 +/- 0.2* 25 +/- 9*
Final OD, 350 nm
10 μM CaCl2 0.198 +/- 0.012† 0.140 +/- 0.017* 0.070 +/- 0.007*
2.0 mM CaCl2 0.231 +/- 0.014 0.160 +/- 0.019* 0.097 +/- 0.021*
5.0 mM CaCl2 0.248 +/- 0.011 0.169 +/- 0.013* 0.103 +/- 0.015*
*
p values < 0.05 compared to γ/γ fibrinogen.
†
p values < 0.05 for 10 μM or 5.0 mM compared to 2.0 mM CaCl2.
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